Lilly just sued six companies selling retatrutide. Their press release calls it “protecting patients” from a “dangerous black market.”
I don’t think so.
This is about protecting a drug that isn’t even approved yet. One that could be worth billions once it is. Six lawsuits aren’t a safety campaign. They’re a warning shot.
Look at where these suits were filed: five of the six are in Texas federal courts. One outlier in California, everything else Texas. That’s not a coincidence, that’s forum shopping.
Lilly’s tried this playbook before and gotten burned. A Delaware judge threw out a similar case and called out Lilly’s “innovative jurisdictional theories” while doing it. Then on August 4, a Texas federal court let Lilly keep pursuing state unfair-competition claims against a different company. Eight days later — six new lawsuits. That timing isn’t subtle.
Here’s the legal maneuver: Lilly can’t enforce federal drug law itself. Only the FDA can do that. So instead, Lilly’s using state unfair-competition statutes to get a similar outcome through private lawsuits — and Texas courts, thanks to recent Fifth Circuit rulings, give them a real shot at making it stick.
And notice who got sued: smaller companies. Companies that probably don’t have the legal budget to go toe-to-toe with one of the biggest drug makers on the planet. That’s the actual strategy — target the vulnerable, bury them in legal costs, force a surrender before any judge actually rules on the merits, then wave the settlements around as a warning to everyone else in the space.
The weirdest part: Lilly wants damages for a product it doesn’t sell. Retatrutide has no FDA approval, no brand name, no commercial release — it’s just the molecule’s name, same as tirzepatide is the molecule behind Mounjaro and Zepbound. You can’t lose sales on something that was never for sale.
And the evidence backing some of this looks flimsy. One complaint reportedly points to a random Trustpilot review. Another cites an old Facebook post where an owner just mentioned NAD and retatrutide together. That’s not proof of anything — that’s a stretch dressed up as a legal filing.
What happens to research-use-only retatrutide from here depends heavily on these six cases. Lilly doesn’t even need to win. Just the cost and fear of fighting a pharma giant could be enough to scare off suppliers, processors, and shipping partners. Right now, the outlook isn’t good.
Here’s the number that tells you everything: at scale, Lilly could probably make a 10mg vial of retatrutide for under a dollar. Look at pricing on comparable obesity drugs and their branded version could land between $600 and $1,000 a month.
That’s the real math here. Lilly isn’t protecting patients from a black market. Lilly’s protecting a markup.
Source: Lilly calls on online platforms, payment companies and regulators to shut down the illegal retatrutide black market, Eli Lilly and Company, Aug. 12, 2026.